Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.

Rhythm Pharmaceuticals Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rhythm Pharmaceuticals (RYTM) and Cardiff Oncology (...

Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (RYTM) and Cardiff Oncology (CRDF)

In a report released today, Seamus Fernandez from Guggenheim reiterated a Buy rating on Rhythm Pharmaceuticals, with a price target of $143.00. Acc...

Guggenheim Remains a Buy on Rhythm Pharmaceuticals (RYTM)

In a report released on May 8, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Rhythm Pharmaceuticals, with a price target of $133.00....

Stifel Nicolaus Remains a Buy on Rhythm Pharmaceuticals (RYTM)

Rhythm Pharmaceuticals (($RYTM)) has held its Q1 earnings call. Read on for the main highlights of the call. Rhythm Pharmaceuticals’ latest earning...

Rhythm Pharmaceuticals Bets Big On Obesity Growth

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ascendis Pharma (ASND) and Rhythm Pharmaceuticals (R...

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND) and Rhythm Pharmaceuticals (RYTM)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rhythm Pharmaceuticals (RYTM), LeonaBio (LONA) and u...

Analysts’ Top Healthcare Picks: Rhythm Pharmaceuticals (RYTM), LeonaBio (LONA)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tonix Pharma (TNXP), Crescent Biopharma (CBIO) and R...

Current Quarter	$-0.84	Next Quarter	$-0.77
Current Year	$-3.18	Next Year	$-0.66
QoQ Growth	+8.3%	YoY Growth	+79.2%
3Y EPS CAGR	+3.6%	Target Price	$138.20
Consensus	Buy	Upside	+51.2%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RYTM	$91.42	+1.78%	495.68K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RYTM	$91.42	+1.8%	495.68K
3
4
5
6

RYTM

RYTM

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Rhythm Pharmaceuticals Inc. Data in Excel

Get Rhythm Pharmaceuticals Inc. Data in Excel